Pricing Log in Create free account
Friday 6 November 2026 Export WAT’s income statement to Excel — free account

Waters Corporation

WAT Healthcare Diagnostics & Research

Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024.

Revenue
+120.9%
EPS
−67.0%
Free cash flow
−66.7%
Total debt
+308.2%

Quarter to September 2026, against a year earlier

460.96 7.88 +1.74%
Market cap
$44.5B
P/E
194×
Fwd P/E
81.0×
Dividend yield
—
F-score
5/9
Altman Z
9.63
Beneish M
−2.37
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Waters Corporation 10-Q filed Aug 4, 2025

Fiscal Q2 2025 · Period ended Jun 28, 2025 · Filed · accepted 6:16 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 6, 2025: 34 added · 6 removed · 28 modified; 4 with only figures updated

  1. Added · Acquisition of Halo Labs

    On May 20, 2025, the Company completed the acquisition of all of the outstanding equity interests of Optofluidics, Inc., and its wholly owned operating subsidiary, Halo Labs LTD (collectively, “Halo Labs”), for $35 million, net of cash acquired. Halo Labs offers high throughput biopharmaceutical formulation, stability and product quality control tools for aggregate and subvisible particle analysis through the use of custom optics and image processing techniques. As a result of the acquisition, the results of Halo Labs are included in the Company’s consolidated financial statements from the acquisition date.